Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
5.56
-0.37 (-6.24%)
At close: Nov 10, 2025, 4:00 PM EST
5.80
+0.24 (4.32%)
After-hours: Nov 10, 2025, 7:57 PM EST
Capricor Therapeutics Revenue
Capricor Therapeutics had revenue of $11.13M in the twelve months ending September 30, 2025, down -52.08% year-over-year. In the year 2024, Capricor Therapeutics had annual revenue of $22.27M, down -11.55%.
Revenue (ttm)
$11.13M
Revenue Growth
-52.08%
P/S Ratio
17.54
Revenue / Employee
$69,566
Employees
160
Market Cap
254.19M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
| Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
| Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
| Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
| Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CAPR News
- 3 hours ago - Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel - GlobeNewsWire
- 10 days ago - Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10 - GlobeNewsWire
- 5 weeks ago - Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation - GlobeNewsWire
- 6 weeks ago - Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026 - Seeking Alpha
- 6 weeks ago - Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway - Seeking Alpha
- 6 weeks ago - Capricor Therapeutics, Inc. - Special Call - Seeking Alpha
- 6 weeks ago - Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting - GlobeNewsWire